Protara Therapeutics (TARA) Cash from Financing Activities (2014 - 2026)

Protara Therapeutics' Cash from Financing Activities history runs 13 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 33.87% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $82.1 million (down 42.03% YoY), while the FY2025 annual figure was $82.7 million, down 40.86% from the prior year.
• Cash from Financing Activities was $1.1 million for Q1 2026 at Protara Therapeutics, down from $81.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $97.8 million in Q4 2024 to a low of -$76000.0 in Q1 2024.
• Historically, Cash from Financing Activities has averaged $18.6 million across 5 years, with a median of $10500.0 in 2025.
• Biggest YoY gain for Cash from Financing Activities was 2376.32% in 2025; the steepest drop was 99.98% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at -$18000.0 in 2022, then tumbled by 50.0% to -$27000.0 in 2023, then soared by 362503.7% to $97.8 million in 2024, then declined by 17.26% to $81.0 million in 2025, then slumped by 98.59% to $1.1 million in 2026.
• The last three Cash from Financing Activities figures came in at $1.1 million (Q1 2026), $81.0 million (Q4 2025), and $13000.0 (Q3 2025), per Business Quant data.